Upexi, Inc. (UPXI) Q2 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerning factors: declining revenue, a net loss, capital constraints, and inventory build-up in the re-commerce business. Although branded product sales increased, they are not sufficient to offset the overall decline. Management's vague responses in the Q&A further add to uncertainty. The positive aspects, such as improved gross margins and cost control, are overshadowed by significant financial challenges, leading to a negative sentiment. Without market cap data, the prediction leans towards a negative stock price movement, likely between -2% to -8%.
Key Financial Performance
Revenue $21.8 million (decreased from $26.7 million year-over-year and $27.3 million sequentially). The decrease was primarily due to lower re-commerce revenue through Amazon channels and wholesale.
Brand Product Sales $7.7 million (increased 16.7% sequentially from $6.6 million). This growth was led by the health and beauty product categories.
Cost of Revenue $13.6 million (decreased from $16.7 million year-over-year and $18.6 million sequentially). The decrease was primarily related to the decrease in re-commerce sales.
Gross Margin 38% (remained the same year-over-year and increased from 31.8% sequentially). The increase was attributed to the growth in brand product sales as a percentage of total revenue.
Sales and Marketing Expense Decreased by 18% year-over-year and approximately $160,000 lower than the first quarter. The decrease was due to management's efforts to refine sales strategies focusing on long-term recurring sales growth.
General and Administrative Expenses $2.3 million (decreased by 9% from $2.5 million year-over-year). Management has managed its general and administrative costs effectively.
Adjusted EBITDA Approximately $29,000 (decreased from approximately $557,000 year-over-year and $750,000 sequentially). The decrease reflects the overall revenue decline.
Net Loss from Continued Operations $2.4 million (compared to net income of $2.7 million year-over-year and a net loss of $1.4 million in the first quarter). The loss was primarily due to decreased revenue.
Cash $1.8 million as of December 31, 2023.
Total Stockholders' Equity Approximately $25.5 million as of December 31, 2023.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Brand Product Sales Growth: Brand product sales during the second quarter increased 16.7% sequentially to $7.7 million, compared to $6.6 million in the prior quarter.
Subscription Revenue Growth: Subscription revenue across health and wellness grew approximately 5% month-over-month.
New Product Offerings: Investments are being made in branded products including Tytan Tiles and Lucky Tail, which are launching new product offerings.
Market Positioning: The company is prioritizing investments in higher-margin brand products and subscription revenue opportunities.
Re-commerce Business Strategy: The decision to reduce risk in purchasing excess inventory in the re-commerce business is aimed at focusing on higher-margin brand business.
Operational Efficiencies: Consolidation of manufacturing facilities expected to save $450,000 to $550,000 per quarter, totaling approximately $2 million annually.
Cost Management: General and administrative expenses decreased by 9% to $2.3 million compared to the previous year.
Strategic Shift: The company is shifting focus towards high-margin recurring revenue brand businesses and reducing reliance on re-commerce.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decrease: Revenue for Q2 2024 decreased to $21.8 million from $27.3 million in Q1 2024, primarily due to lower re-commerce revenue through Amazon channels and wholesale.
Inventory Management Risk: The company made a calculated decision to reduce the risk of purchasing excess inventory in the re-commerce business, which impacted revenue.
Market Conditions: The business is navigating challenging market conditions, which may affect profitability and growth.
Capital Constraints: Capital constraints are leading the company to prioritize investments in higher-margin brand products, which could limit growth in other areas.
Net Loss: The company reported a net loss of $2.4 million for Q2 2024, compared to a net income of $2.7 million in the same period last year.
Advertising and Marketing Strategy: Management anticipates that advertising expenses will be reduced over time as a percentage of sales, which may impact short-term growth.
Consolidation of Manufacturing Facilities: The consolidation of operations is expected to yield cost savings of $450,000 to $550,000 per quarter, but may pose risks during the transition period.
Subscription Revenue Growth: While subscription revenue is growing, reliance on this model may expose the company to risks if customer acquisition costs rise.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Gross Profit Margin: Increased to 38% from 31.8% in the prior fiscal first quarter.
Brand Product Sales Growth: Increased 16.7% sequentially to $7.7 million from $6.6 million.
Manufacturing Consolidation Savings: Expected cost savings of $450,000 to $550,000 per quarter, totaling approximately $2 million annually.
Investment in High-Margin Brands: Prioritizing investments in higher-margin brand products through subscription revenue opportunities.
Acne Study Data: Anticipated data from the acne study expected to significantly increase sales in the health and wellness segment.
Revenue Expectations: Revenue for fiscal Q2 2024 totaled $21.8 million, down from $26.7 million year-over-year.
Adjusted EBITDA: Expected to improve as management focuses on high-margin brand product sales and subscription revenue.
Sales and Marketing Strategy: Management anticipates advertising expenses will decrease as a percentage of sales, increasing overall profitability.
Long-term Growth Confidence: Management expresses confidence in driving long-term growth, innovation, and value creation.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: The company has not announced any share buyback program or dividend program during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Was the softness in the re-commerce business due to pricing or last-minute changes?
A:Some of it was timing when it comes in and when it goes out. We didn't see opportunities that met our margin profile, and we are pushing for higher margins on deals.
Q:Is the margin hurdle higher now or are there just fewer opportunities?
A:We've seen good opportunities but decided to focus more on the brand business. Margins available may not be as high as before, but we expect opportunities to increase after the holidays.
Q:Was Tytan Tiles a significant contributor to the growth in health and beauty?
A:Yes, Tytan is evolving into brick and mortar, and we are looking to bring Disney products back to DTC. Our other brands have higher margins and are primarily direct-to-consumer.
Q:How do you see the split between e-commerce and brick-and-mortar growth?
A:We will continue to grow in all aspects, but the bulk of our business will remain direct-to-consumer with higher margins.
Q:Review of Unclear Management Responses
A:Management's responses lacked clarity on the specific reasons for the softness in the re-commerce business and the exact margin hurdles they are facing. There was also vague language regarding the future opportunities in the re-commerce sector.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Amazon beginning
Amazon channel
Brand percentage
Communications Chief
Communications evening
Conference event
Consolidation increase
Cost decrease
DTC
Pinto Managing
brand business
brand margin
brand product
brand today
brick mortar
capital constraint
commerce margin
deal
decrease period
decrease sale
end
flow result
health beauty
hurdle opportunity
margin brand
margin hurdle
margin profile
market condition
percentage sale
period loss
pricing
queue
reinvestment
sale channel
sale margin
value brand
UPXI Transcript
Upexi, Inc. (UPXI) Q3 2026 Earnings Call Transcript
Positive5-12
The earnings call summary shows strong financial performance with a 20% YoY revenue increase, improved gross margins, and a 50% rise in net income. Despite a rise in operating expenses, the overall financial health appears robust, with increased cash flow from operations. The absence of strategic, operational, and risk discussions limits the assessment scope, but the financials alone suggest a positive outlook. Given the lack of market cap data, the typical stronger reaction of small-cap stocks to positive financials is assumed, leading to a 'Positive' sentiment rating.
Upexi, Inc. (UPXI) Q2 2026 Earnings Call Transcript
Unknown2-10
The earnings call presents a mixed picture: a strong revenue increase and a $50 million share repurchase program are positive, but there are significant concerns. The net loss driven by unrealized losses on digital assets, high treasury expenses, and stock compensation are negatives. The Q&A revealed cautious capital management and lack of clarity on future strategies. Overall, the positive elements are counterbalanced by financial and strategic uncertainties, resulting in a neutral sentiment.
Upexi, Inc. (UPXI) Q1 2026 Earnings Call Transcript
Positive11-11
The earnings call highlights strong financial performance driven by Solana, including significant revenue and net income growth. The company is optimistic about regulatory changes, which could boost blockchain adoption. While there are risks related to market volatility and strategic execution, the focus on Solana and potential regulatory support are positive indicators. The Q&A reveals confidence in yield improvements and shareholder strategies. Despite some uncertainties, the overall sentiment is positive, with the potential for a stock price increase of 2% to 8% over the next two weeks.
Upexi, Inc. (UPXI) Q2 2024 Earnings Call Transcript
Unknown2-15
The earnings call reveals several concerning factors: declining revenue, a net loss, capital constraints, and inventory build-up in the re-commerce business. Although branded product sales increased, they are not sufficient to offset the overall decline. Management's vague responses in the Q&A further add to uncertainty. The positive aspects, such as improved gross margins and cost control, are overshadowed by significant financial challenges, leading to a negative sentiment. Without market cap data, the prediction leans towards a negative stock price movement, likely between -2% to -8%.
UPXI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
